Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Emergence of fluoroquinolone resistance in Mycobacterium tuberculosis during continuously dosed moxifloxacin monotherapy in a mouse model.

Literature DB >> 16127087

Emergence of fluoroquinolone resistance in Mycobacterium tuberculosis during continuously dosed moxifloxacin monotherapy in a mouse model.

Amy Sarah Ginsburg¹, Ronggai Sun, Heather Calamita, Cherise P Scott, William R Bishai, Jacques H Grosset.

Abstract

Fluoroquinolone resistance in tuberculosis may rapidly emerge. Mice infected with high titers of aerosolized Mycobacterium tuberculosis and treated for 8 weeks with four concentrations of moxifloxacin (0.125, 0.25, 0.50, and 1.0%) mixed into the diet had drug concentrations of 2.4, 4.1, 5.3, and 17.9 microg/ml, respectively, in blood. Selection of fluoroquinolone-resistant mutants occurred in all surviving mice.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2005 PMID： 16127087 PMCID： PMC1195434 DOI： 10.1128/AAC.49.9.3977-3979.2005

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

12 in total

1. Development of fluoroquinolones as first-line drugs for tuberculosis--at long last!

Authors: Richard J O'Brien
Journal: Am J Respir Crit Care Med Date: 2003-12-01 Impact factor: 21.405

2. The rapid development of fluoroquinolone resistance in M. tuberculosis.

Authors: Amy Sarah Ginsburg; Samuel C Woolwine; Nancy Hooper; William H Benjamin; William R Bishai; Susan E Dorman; Timothy R Sterling
Journal: N Engl J Med Date: 2003-11-13 Impact factor: 91.245

3. Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis.

Authors: E Miyazaki; M Miyazaki; J M Chen; R E Chaisson; W R Bishai
Journal: Antimicrob Agents Chemother Date: 1999-01 Impact factor: 5.191

Review 4. Treatment of multidrug-resistant tuberculosis.

Authors: M D Iseman
Journal: N Engl J Med Date: 1993-09-09 Impact factor: 91.245

5. Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations.

Authors: H E Takiff; L Salazar; C Guerrero; W Philipp; W M Huang; B Kreiswirth; S T Cole; W R Jacobs; A Telenti
Journal: Antimicrob Agents Chemother Date: 1994-04 Impact factor: 5.191

Review 6. Fluoroquinolones, tuberculosis, and resistance.

Authors: Amy Sarah Ginsburg; Jacques H Grosset; William R Bishai
Journal: Lancet Infect Dis Date: 2003-07 Impact factor: 25.071

7. Gyrase mutations in laboratory-selected, fluoroquinolone-resistant mutants of Mycobacterium tuberculosis H37Ra.

Authors: T Kocagöz; C J Hackbarth; I Unsal; E Y Rosenberg; H Nikaido; H F Chambers
Journal: Antimicrob Agents Chemother Date: 1996-08 Impact factor: 5.191

8. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis.

Authors: Eric L Nuermberger; Tetsuyuki Yoshimatsu; Sandeep Tyagi; Richard J O'Brien; Andrew N Vernon; Richard E Chaisson; William R Bishai; Jacques H Grosset
Journal: Am J Respir Crit Care Med Date: 2003-10-24 Impact factor: 21.405

9. Emergence of fluoroquinolone-resistant tuberculosis in New York City.

Authors: E A Sullivan; B N Kreiswirth; L Palumbo; V Kapur; J M Musser; A Ebrahimzadeh; T R Frieden
Journal: Lancet Date: 1995-05-06 Impact factor: 79.321

10. Fluoroquinolone resistance in patients with newly diagnosed tuberculosis.

Authors: Amy Sarah Ginsburg; Nancy Hooper; Nikki Parrish; Kelly E Dooley; Susan E Dorman; Jay Booth; Marie Diener-West; William G Merz; William R Bishai; Timothy R Sterling
Journal: Clin Infect Dis Date: 2003-11-04 Impact factor: 9.079

15 in total

Review 1. An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future.

Authors: Jotam Pasipanodya; Tawanda Gumbo
Journal: Antimicrob Agents Chemother Date: 2010-10-11 Impact factor: 5.191

2. Pharmacokinetic/pharmacodynamic analysis of the influence of inoculum size on the selection of resistance in Escherichia coli by a quinolone in a mouse thigh bacterial infection model.

Authors: Aude A Ferran; Anne-Sylvie Kesteman; Pierre-Louis Toutain; Alain Bousquet-Mélou
Journal: Antimicrob Agents Chemother Date: 2009-06-01 Impact factor: 5.191

Review 3. Current prospects for the fluoroquinolones as first-line tuberculosis therapy.

Authors: Howard Takiff; Elba Guerrero
Journal: Antimicrob Agents Chemother Date: 2011-08-29 Impact factor: 5.191

4. Effect of coadministration of moxifloxacin and rifampin on Mycobacterium tuberculosis in a murine aerosol infection model.

Authors: V Balasubramanian; S Solapure; S Gaonkar; K N Mahesh Kumar; R K Shandil; Abhijeet Deshpande; Naveen Kumar; K G Vishwas; Vijender Panduga; Jitendar Reddy; Samit Ganguly; A Louie; G L Drusano
Journal: Antimicrob Agents Chemother Date: 2012-04-02 Impact factor: 5.191

5. Of Testing and Treatment: Implications of Implementing New Regimens for Multidrug-Resistant Tuberculosis.

Authors: David W Dowdy; Grant Theron; Jeffrey A Tornheim; Robin Warren; Emily A Kendall
Journal: Clin Infect Dis Date: 2017-10-01 Impact factor: 9.079

Review 6. The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells.

Authors: Véronique Dartois
Journal: Nat Rev Microbiol Date: 2014-02-03 Impact factor: 60.633

7. Emergence of ofloxacin resistance in Mycobacterium tuberculosis clinical isolates from China as determined by gyrA mutation analysis using denaturing high-pressure liquid chromatography and DNA sequencing.

Authors: Ruiru Shi; Jianyuan Zhang; Chuanyou Li; Yuko Kazumi; Isamu Sugawara
Journal: J Clin Microbiol Date: 2006-10-11 Impact factor: 5.948